The Role of Real-World Evidence in CMS Price Negotiations

By Melike Belenli Gümüş

June 28, 2024

Introduction

The role of real-world evidence (RWE) in the Centers for Medicare & Medicaid Services (CMS) price negotiations is becoming increasingly significant. As CMS embark on drug price negotiations, the integration of RWE is crucial. This article explored the importance of RWE, the challenges faced, and recommendations for a robust framework.

The Importance of Real-World Evidence

Randomised controlled trials (RCTs) are the gold standard for assessing treatment efficacy and safety. However, they often exclude patients who represent the broader population. This is where RWE comes into play. RWE, derived from real-world data (RWD) such as claims and electronic health records (EHRs), provides a comprehensive view of a drug’s performance in everyday clinical practice.

RWE is particularly valuable for CMS as it considers drugs that have been on the market for at least seven years. This allows sufficient time for RWD to accumulate, offering insights into the drug’s effectiveness in various patient populations. For instance, a study found that RWE can help understand therapeutic alternatives and unmet needs, which are critical for CMS’s price-setting decisions.

Health Technology Assessment and RWE

Health technology assessment (HTA) agencies, such as NICE in the UK, have long relied on comparative effectiveness research to guide their decisions. These agencies often use RWE to answer important post-marketing questions about a drug’s performance in real-world settings. For example, NICE has conducted comparative effectiveness and safety studies using RWE to inform their evaluations.

CMS can learn from the experiences of international HTA agencies in integrating RWE into their decision-making processes. By adopting similar methodologies, CMS can ensure that their price negotiations are informed by the most comprehensive and reliable evidence available.

Challenges in Generating High-Quality RWE

Despite its potential, generating high-quality RWE is not without challenges. One major hurdle is the availability of fit-for-purpose RWD. High-quality data is essential for producing robust RWE studies. CMS must invest in improving its claims data infrastructure to ensure data quality and accessibility.

Moreover, linking CMS claims data with other sources, such as EHRs, can provide a more complete picture of patient outcomes. This linkage is vital for capturing all necessary data elements, including outcomes and confounders. Without a robust RWD infrastructure, the generation of high-quality RWE studies remains challenging.

Figure 1: Boxplots of the ranking of the barriers to accepting RWD in HTA or decision-making. The barriers are placed in order of their median ranked score and the mean scores are listed between brackets on the left side. (Reproduced from https://doi.org/10.3389/fphar.2022.837302)

Recommendations for a Robust RWE Framework

To promote the generation of transparent and high-quality RWE studies, CMS should establish clear standards for evaluating RWE. Agencies such as NICE and the FDA have delineated guidelines defining the criteria for high-quality RWE. These guidelines can serve as a starting point for CMS to develop its own standards.

CMS should also invest in internal experts in fields such as pharmacoepidemiology, health outcomes research, data science, and biostatistics. These experts can help ensure that RWE studies meet the necessary methodological rigour. Also, CMS should develop clear parameters for when it will conduct its own RWE studies and how these studies will comply with established standards.

The Future of RWE in CMS Price Negotiations

The integration of RWE in CMS price negotiations holds great promise. By committing to using RWE and providing clear standards, CMS can incentivise researchers to generate high-quality studies. This, in turn, will ensure that drug pricing and value decisions are based on the best available evidence.

In conclusion, RWE is poised to play a significant role in CMS price negotiations. However, to fully realise its potential, CMS must address the challenges of data quality and accessibility. By investing in a robust RWD infrastructure and establishing clear standards for RWE, CMS can ensure that its price-setting decisions are informed by the most reliable evidence.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.